within Pharmacolibrary.Drugs.ATC.M;

model M05BX05
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 4.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BX05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Burosumab is a fully human monoclonal antibody targeting fibroblast growth factor 23 (FGF23). It is used for the treatment of X-linked hypophosphatemia (XLH) in adults and children 1 year of age and older. It is an approved drug for this indication in the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult and pediatric patients with X-linked hypophosphatemia following subcutaneous administration. Based on population PK analysis.</p><h4>References</h4><ol><li><p>Lamb, YN (2018). Burosumab: First Global Approval. <i>Drugs</i> 78(6) 707–714. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0905-7&quot;>10.1007/s40265-018-0905-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29679282/&quot;>https://pubmed.ncbi.nlm.nih.gov/29679282</a></p></li><li><p>Lee, SK, et al., &amp; Shi, J (2022). Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked Hypophosphatemia. <i>Journal of clinical pharmacology</i> 62(1) 87–98. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1950&quot;>10.1002/jcph.1950</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34352114/&quot;>https://pubmed.ncbi.nlm.nih.gov/34352114</a></p></li><li><p>Zhang, X, et al., &amp; Peacock, M (2016). Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. <i>Journal of clinical pharmacology</i> 56(2) 176–185. DOI:<a href=&quot;https://doi.org/10.1002/jcph.570&quot;>10.1002/jcph.570</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26073451/&quot;>https://pubmed.ncbi.nlm.nih.gov/26073451</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BX05;
